Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics and distribution of SLC39A6 rs1050631 genotypes

From: Involvement of SLC39A6 in gastric adenocarcinoma and correlation of the SLC39A6 polymorphism rs1050631 with clinical outcomes after resection

VariablesPatients
N (%)
SLC39A6 rs1050631 genotype (N)P*Pdominant aPadditive b
TT(%)CT(%)CC(%)
Total51220 (3.9)139 (27.1)353 (69.0)   
Age0.260.250.14
  < 60235 (45.9)6 (1.2)61 (11.9)168 (32.8)   
  ≥ 60277 (54.1)14 (2.7)78 (15.2)185 (36.1)   
Gender0.380.180.25
 Male383 (74.8)15 (2.9)110 (21.5)258 (50.4)   
 Female129 (25.2)5 (1.0)29 (5.7)95 (18.5)   
Grade of differentiation0.850.930.86
 Well differentiated21 (4.1)1 (0.2)6 (1.2)14 (2.7)   
 Moderately differentiated263 (51.4)9 (1.8)75 (14.6)179 (35.0)   
 Poorly differentiated228 (44.5)10 (2.0)58 (11.3)160 (31.2)   
Gross findings0.790.960.81
 Apophysis35 (6.8)2 (0.4)9 (1.8)24 (4.7)   
 Invasion477 (93.2)18 (3.5)130 (25.4)329 (64.3)   
Lauren classification0.650.450.22
 Intestinal type420 (82.1)18 (3.5)119 (23.2)283 (55.3)   
 Diffuse type81 (15.8)2 (0.4)18 (3.5)61((11.9))   
 Uncertain type11 (2.1)0 (0)2 (0.4)9 (1.8)   
Tumor location0.320.380.42
 Upper third179 (35.0)4 (0.8)52 (10.2)123 (24.0)   
 Middle third78 (15.2)4 (0.8)16 (3.1)58 (11.3)   
 Lower third252 (49.2)12 (2.3)69 (13.5)171 (33.4)   
 Total3 (0.6)0 (0)2 (0.4)1 (0.2)   
Tumor size0.990.880.92
  ≥ 5 cm210 (41.0)8 (1.6)58 (11.3)144 (28.1)   
  < 5 cm302 (59.0)12 (2.3)81 (15.8)209 (40.8)   
Survival0.002< 0.001< 0.001
 Alive182 (35.5)4 (0.4)35 (6.8)143 (27.9)   
 Dead330 (64.5)16 (3.1)104 (20.3)210 (41.0)   
Recurrence0.004< 0.001< 0.001
 Yes334 (65.2)16 (3.1)104 (20.3)214 (41.8)   
 No178 (34.8)4 (0.8)35 (6.8)139 (27.1)   
Distant metastasis0.430.870.81
 Yes63 (12.3)4 (0.8)15 (2.9)44 (8.6)   
 No449 (87.7)16 (3.1)124 (24.2)309 (60.4)   
Lymph node metastasis0.120.210.08
 Yes398 (77.7)19 (3.7)110 (21.5)269 (52.5)   
 No114 (22.3)1 (0.2)29 (5.7)84 (16.4)   
Chemotherapy
 Yes329 (64.3)13 (2.5)93 (18.2)223 (43.6)0.610.780.69
 No183 (35.7)7 (1.4)46 (9.0)130 (25.4)   
  1. * The χ2 test was used to calculate p values. Fisher’s exact test was used in the analysis of contingency tables when sample size was smaller than 5
  2. a Logistic regression analysis for the dominant model (TT + CT vs CC) was used to calculate the p value
  3. b Logistic regression analysis for the log-additive model was used to calculate the p value by comparing the effect of each additional variant allele